Zoekresultaten - L Rimsky

  • Toon 1 - 15 resultaten van 15
Verfijn jouw resultaten
  1. 1
    Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides

    Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides door L Rimsky, Diane C. Shugars, Thomas J. Matthews

    Gepubliceerd in 1998
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  2. 2
    96-Week Resistance Analyses of Rilpivirine in Treatment-Naive, HIV-1-Infected Adults from the Echo and Thrive Phase Iii Trials

    96-Week Resistance Analyses of Rilpivirine in Treatment-Naive, HIV-1-Infected Adults from the Echo and Thrive Phase Iii Trials door L Rimsky, Veerle Van Eygen, Annemie Hoogstoel, Marita Stevens, Katia Boven, Gastón Picchio, Johan Vingerhoets

    Gepubliceerd in 2013
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  3. 3
    Epstein-Barr virus-containing B-cell line produces an interleukin 1 that it uses as a growth factor.

    Epstein-Barr virus-containing B-cell line produces an interleukin 1 that it uses as a growth factor. door Hiro Wakasugi, L Rimsky, Yann F. Mahé, Azza M. Kamel, D Fradelizi, Thomas Tursz, Jacques Bertoglio

    Gepubliceerd in 1987
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  4. 4
    Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies

    Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies door L Rimsky, Johan Vingerhoets, Veerle Van Eygen, Joseph J. Eron, Bonaventura Clotet, Annemie Hoogstoel, Katia Boven, Gastón Picchio

    Gepubliceerd in 2011
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  5. 5
    Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors

    Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors door Lotke Tambuyzer, Hilde Azijn, L Rimsky, Johan Vingerhoets, Pierre Lecocq, Guenter Kraus, Gastón Picchio, Marie‐Pierre de Béthune

    Gepubliceerd in 2009
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  6. 6
    Cloning and expression of a cDNA for human thioredoxin.

    Cloning and expression of a cDNA for human thioredoxin. door E Wollman, L d'Auriol, L Rimsky, Alan Shaw, Jean‐Pierre Jacquot, Paul T. Wingfield, Pierre Graber, Françoise Dessarps, Philippe Robin, Francis Galibert

    Gepubliceerd in 1988
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  7. 7
    The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness

    The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness door Rima Kulkarni, Kerim Babaoglu, E.B. Lansdon, L Rimsky, Veerle Van Eygen, Gastón Picchio, Evguenia S. Svarovskaia, Michael D. Miller, Kirsten L. White

    Gepubliceerd in 2011
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  8. 8
    TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

    TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1 door Hilde Azijn, Ilse Tirry, Johan Vingerhoets, Marie‐Pierre de Béthune, Guenter Kraus, Katia Boven, Dirk Jochmans, Elke Van Craenenbroeck, Gastón Picchio, L Rimsky

    Gepubliceerd in 2009
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  9. 9
    Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

    Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial door Anton Pozniak, Javier O Morales-Ramirez, Elly Katabira, Dewald Steyn, Sergio Lupo, Mario Santoscoy, Beatriz Grinsztejn, Kiat Ruxrungtham, L Rimsky, Simon Vanveggel, Katia Boven

    Gepubliceerd in 2009
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  10. 10
    Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1

    Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1 door Marc Girard, Bernard Meignier, Françoise Barré‐Sinoussi, M. P. Kieny, Thomas J. Matthews, Elizabeth Muchmore, Peter L. Nara, Qing Wei, L Rimsky, Kent J. Weinhold

    Gepubliceerd in 1995
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  11. 11
    Stimulation of the human immunodeficiency virus type 1 enhancer by the human T-cell leukemia virus type I tax gene product involves the action of inducible cellular proteins

    Stimulation of the human immunodeficiency virus type 1 enhancer by the human T-cell leukemia virus type I tax gene product involves the action of inducible cellular proteins door Ernst Böhnlein, Miriam Siekevitz, Dean W. Ballard, John W. Lowenthal, L Rimsky, Hal P. Bogerd, J A Hoffman, Yuji Wano, B. Robert Franza, Warner C. Greene

    Gepubliceerd in 1989
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  12. 12
    Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements.

    Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements. door S M Hanly, L Rimsky, Michael H. Malim, J H Kim, Joachim Hauber, Madeleine Duc Dodon, Shu‐Yun Le, Jacob V. Maizel, Bryan R. Cullen, Warner C. Greene

    Gepubliceerd in 1989
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  13. 13
    Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment‐naïve, HIV‐1‐infected patients

    Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment‐naïve, HIV‐1‐infected patients door Cal Cohen, Jean‐Michel Molina, Pedro Cahn, Bonaventura Clotet, Jan Fourie, Beatriz Grinsztejn, Wei Hao, Margaret Johnson, K Supparatpinyo, HM Crauwels, L Rimsky, Simon Vanveggel, Paige Williams, Katia Boven

    Gepubliceerd in 2010
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  14. 14
    Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

    Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials door Calvin Cohen, Jean‐Michel Molina, Isabel Cassetti, Ploenchan Chetchotisakd, Adriano Lazzarin, Chloe Orkin, Frank S. Rhame, Hans-Jürgen Stellbrink, Taisheng Li, Herta Crauwels, L Rimsky, Simon Vanveggel, Peter Williams, Katia Boven

    Gepubliceerd in 2012
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  15. 15
    Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients

    Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients door Calvin Cohen, Jean‐Michel Molina, Pedro Cahn, Bonaventura Clotet, Jan Fourie, Beatriz Grinsztejn, Hao Wu, Margaret Johnson, Michael S. Saag, Khuanchai Supparatpinyo, Herta Crauwels, Éric Lefebvre, L Rimsky, Simon Vanveggel, Peter Williams, Katia Boven

    Gepubliceerd in 2012
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:

Zoekinstrumenten: